Conference Day 1

8:30 am Registration & Coffee

9:15 am Chair’s Opening Remarks

Elucidating the Mechanisms of Action of TIGIT Therapies to Inform Future Drug Development

9:30 am Targeting Cell Populations Within the Tumor Microenvironment (TME) with TIGIT Antagonist Antibodies

10:00 am Providing the Latest Insights into the Mechanism of Action of Anti-TIGIT Targeting Therapies to Inform Effective Combination Strategies & Future Development Settings

  • Vijay Kuchroo Director Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigam and Women's Hospital

10:30 am Exploiting TIGIT’s Mechanism to Target Glioblastoma

  • Michael Lim Chair of Neurosurgery, Stanford University

11:00 am Morning Refreshments & Speed Networking

FcγR-Binding – Developing this Important Functional Attribute for Immune Checkpoint Antibodies

11:30 am Targeting TIGIT: Which Cell Populations are Modulated by FcγR Engagement?

12:00 pm Discussing Evidence for FcγR Engagement Dependence for Anti-TIGIT Activity & Leveraging Non-Fucosylation to Improve Anti-Tumor Activity

12:30 pm Panel Session on Fc Binding for Effector Function: What Have We Learnt?

1:15 pm Lunch & Networking

Harnessing TIGIT Action Across Therapeutic Modalities to Rationalize Combination Strategies

2:30 pm Anti-TIGIT Agents Display Combinatorial Activity Across Therapeutic Modalities That Synergize With its Mechanism of Action

3:00 pm Panel Session: Making Sense of the Anti-Tumor Immunity of TIGIT and PD-1 Dual Checkpoint Blockade

  • Kartik Krishnan Vice President, Clinical Development, Arcus Biosciences
  • Marc Ballas Vice President Oncology Clinical Development, GlaxoSmithKline

3:30 pm Afternoon Refreshments & Networking

Examining the Clinical Trial Landscape for Treating Solid & Hematologic Malignancies using TIGIT Targeting Therapies

4:00 pm Sharing an Overview of the Current Development, Clinical Trials & Key Players in the Clinical Trial Landscape of TIGIT Therapies

4:30 pm Providing Updates on Etigilimab’s Clinical Development Strategy in Gynaecologic and Rare Cancer

  • Ann Kapoun Senior Vice President Translational Research & Development, Mereo BioPharma
  • Suba Krishnan Senior Vice President Clinical Development, Mereo BioPharma

5:00 pm Chair’s Closing Remarks